Semin Thromb Hemost 2014; 40(03): 332-336
DOI: 10.1055/s-0034-1370792
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Unique Hemostatic Dysfunction in Acute Promyelocytic Leukemia

Hau C. Kwaan
1   Division of Hematology/Oncology, Olson Pavilion, Chicago, Illinois
› Author Affiliations
Further Information

Publication History

Publication Date:
03 March 2014 (online)

Abstract

The hemostatic abnormalities seen in acute promyelocytic leukemia (APL) are unique and account for much of the morbidity and mortality of this disorder. Almost all patients present at diagnosis with laboratory findings of intravascular coagulation along with increased fibrinolysis. This unusual combination is correlated to the clinical manifestations with high risk of both bleeding and thrombosis. Recent studies have revealed that the leukemic promyelocytes in APL express increased amounts of tissue factor as well as elements of the fibrinolytic system, including tissue plasminogen activator, annexin A2, and plasminogen activator inhibitor type 1. These changes are responsive to differentiation therapy with all-trans-retinoic acid (ATRA) or with arsenic trioxide (ATO). Despite a dramatic reduction in mortality seen since the introduction of differentiation therapy with ATRA or with ATO, a large number of deaths still occur before complete remission is achieved. The early deaths are mostly attributable to the presenting coagulopathy. The prevention and management of this hemostatic abnormality have thus far been unsuccessful and remain a challenge to bring about a higher cure rate for this disease.

 
  • References

  • 1 Croizat P, Favre-Gilly J, Morel P. Les aspects du syndrome hemorrhagiue des leucemies. Sang 1949; 20: 417-421
  • 2 Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand 1957; 159 (3) 189-194
  • 3 Rand JJ, Moloney WD, Sise HS. Coagulation defects in acute promyelocytic leukemia. Arch Intern Med 1969; 123 (1) 39-47
  • 4 Di Bona E, Avvisati G, Castaman G , et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000; 108 (4) 689-695
  • 5 Stein E, McMahon B, Kwaan H, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 2009; 22 (1) 153-163
  • 6 Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol 2012; 156 (1) 24-36
  • 7 Choudhry A, DeLoughery TG. Bleeding and thrombosis in acute promyelocytic leukemia. Am J Hematol 2012; 87 (6) 596-603
  • 8 Kwaan HC, Huyck T. Thromboembolic and bleeding complications in acute leukemia. Expert Rev Hematol 2010; 3 (6) 719-730
  • 9 Kwaan HC, Cull EH. The coagulopathy in acute promyelocytic leukaemia – what have we learned in the past twenty years. Bailliere's Best Practice & Research in Clinical Hematology on Acute Promyelocytic Leukemia 2014; ; In press
  • 10 de la Serna J, Montesinos P, Vellenga E , et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111 (7) 3395-3402
  • 11 Fenaux P. Management of acute promyelocytic leukemia. Eur J Haematol 1993; 50 (2) 65-73
  • 12 Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91 (9) 3093-3102
  • 13 Yanada M, Matsushita T, Asou N , et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol 2007; 78 (3) 213-219
  • 14 De Stefano V, Sorà F, Rossi E , et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005; 3 (9) 1985-1992
  • 15 Ziegler S, Sperr WR, Knöbl P , et al. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res 2005; 115 (1-2) 59-64
  • 16 Breccia M, Avvisati G, Latagliata R , et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia 2007; 21 (1) 79-83
  • 17 Riccio JA, Colley AT, Cera PJ. Hepatic vein thrombosis (Budd-Chiari syndrome) in the microgranular variant of acute promyelocytic leukemia. Am J Clin Pathol 1989; 92 (3) 366-371
  • 18 Myers TJ, Rickles FR, Barb C, Cronlund M. Fibrinopeptide A in acute leukemia: relationship of activation of blood coagulation to disease activity. Blood 1981; 57 (3) 518-525
  • 19 Bauer KA, Rosenberg RD. Thrombin generation in acute promyelocytic leukemia. Blood 1984; 64 (4) 791-796
  • 20 Tallman MS, Lefèbvre P, Baine RM , et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004; 2 (8) 1341-1350
  • 21 Falanga A, Barbui T. Coagulopathy of acute promyelocytic leukemia. Acta Haematol 2001; 106 (1-2) 43-51
  • 22 Kwaan HC, Wang J, Boggio LN. Abnormalities in hemostasis in acute promyelocytic leukemia. Hematol Oncol 2002; 20 (1) 33-41
  • 23 Zhu J, Guo WM, Yao YY , et al. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia 1999; 13 (7) 1062-1070
  • 24 Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25 (14) 4007-4020
  • 25 Wang J, Weiss I, Svoboda K, Kwaan HC. Thrombogenic role of cells undergoing apoptosis. Br J Haematol 2001; 115 (2) 382-391
  • 26 Zhao W, Wang X, Guo W , et al. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment. Chin Med J (Engl) 2000; 113 (3) 236-240
  • 27 Watanabe R, Murata M, Takayama N , et al; Keio Hematology-Oncology Cooperative Study Group (KHOCS). Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Thromb Haemost 1997; 77 (4) 641-645
  • 28 Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol 1989; 71 (4) 511-517
  • 29 Sakata Y, Murakami T, Noro A, Mori K, Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991; 77 (9) 1949-1957
  • 30 Avvisati G, ten Cate JW, Sturk A, Lamping R, Petti MG, Mandelli F. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol 1988; 70 (1) 43-48
  • 31 Falanga A, Iacoviello L, Evangelista V , et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 1995; 86 (3) 1072-1081
  • 32 Falanga A, Russo L, Tartari CJ. Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia. Mediterr J Hematol Infect Dis 2011; 3 (1) e2011068
  • 33 Booth NA, Bennett B. Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis. Br J Haematol 1984; 56 (4) 545-556
  • 34 Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340 (13) 994-1004
  • 35 Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994; 269 (33) 21191-21197
  • 36 Meijers JC, Oudijk EJ, Mosnier LO , et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000; 108 (3) 518-523
  • 37 Kwaan HC, Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin. J Thromb Haemost 2004; 2 (2) 306-312
  • 38 Kwaan HC, Rego EM. Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost 2010; 36 (8) 917-924
  • 39 Ma G, Liu F, Lv L, Gao Y, Su Y. Increased promyelocytic-derived microparticles: a novel potential factor for coagulopathy in acute promyelocytic leukemia. Ann Hematol 2013; 92 (5) 645-652
  • 40 Dombret H, Scrobohaci ML, Ghorra P , et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia 1993; 7 (1) 2-9
  • 41 Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75 (11) 2112-2117
  • 42 Sanz MA, Martín G, González M , et al; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103 (4) 1237-1243
  • 43 Hashimoto S, Koike T, Tatewaki W , et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 1994; 8 (7) 1113-1115
  • 44 Mahendra P, Keeling DM, Hood IM, Baglin TP, Marcus RE. Fatal thromboembolism in acute promyelocytic leukaemia treated with a combination of all-trans retinoic acid and aprotonin. Clin Lab Haematol 1996; 18 (1) 51-52
  • 45 Brown JE, Olujohungbe A, Chang J , et al. All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia. Br J Haematol 2000; 110 (4) 1010-1012
  • 46 Nosari A, Caimi TM, Zilioli V, Molteni A, Mancini V, Morra E. Cerebral hemorrhage treated with NovoSeven in acute promyelocytic leukemia. Leuk Lymphoma 2012; 53 (1) 160-161
  • 47 Zver S, Andoljsek D, Cernelc P. Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. Eur J Haematol 2004; 72 (6) 455-456
  • 48 Alimoghaddam K, Ghavamzadeh A, Jahani M. Use of Novoseven for arsenic trioxide-induced bleeding in PML. Am J Hematol 2006; 81 (9) 720
  • 49 Kawano N, Kuriyama T, Yoshida S , et al. Clinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institution. Intern Med 2013; 52 (1) 55-62
  • 50 Saito H, Maruyama I, Shimazaki S , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5 (1) 31-41
  • 51 Kawano N, Yoshida S, Ono N , et al. Clinical features and outcomes of 35 disseminated intravascular coagulation cases treated with recombinant human soluble thrombomodulin at a single institution. J Clin Exp Hematop 2011; 51 (2) 101-107
  • 52 Sanz MA, Grimwade D, Tallman MS , et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113 (9) 1875-1891
  • 53 Altman JK, Rademaker A, Cull E , et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res 2013; 37 (9) 1004-1009
  • 54 Dunoyer-Geindre S, Kruithof EK. Epigenetic control of tissue-type plasminogen activator synthesis in human endothelial cells. Cardiovasc Res 2011; 90 (3) 457-463